Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting …
MJ Palte, A Wehr, M Tawa, K Perkin… - Advances in …, 2019 - Springer
Introduction Diroximel fumarate (DRF) is a novel oral fumarate in development for patients
with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development …
with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development …
Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing–remitting multiple …
RT Naismith, A Wundes, T Ziemssen, E Jasinska… - CNS drugs, 2020 - Springer
Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for
relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the …
relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the …
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the …
A Wundes, S Wray, R Gold, BA Singer… - Therapeutic …, 2021 - journals.sagepub.com
Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms
of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) …
of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) …
Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study
S Wray, F Then Bergh, A Wundes, DL Arnold… - Advances in …, 2022 - Springer
Introduction Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis
(MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy …
(MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy …
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
RT Naismith, JS Wolinsky, A Wundes… - Multiple Sclerosis …, 2020 - journals.sagepub.com
Background: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–
remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield …
remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield …
[HTML][HTML] Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate
D Wynn, TW Lategan, TN Sprague… - Multiple sclerosis and …, 2020 - Elsevier
Background Monomethyl fumarate (MMF) is the pharmacologically active metabolite of
dimethyl fumarate (DMF). MMF formulated as Bafiertam™ 190 mg and DMF formulated as …
dimethyl fumarate (DMF). MMF formulated as Bafiertam™ 190 mg and DMF formulated as …
Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study
J Theodore Phillips, AA Erwin, S Agrella… - Neurology and …, 2015 - Springer
Introduction Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF)
is indicated for the treatment of patients with relapsing multiple sclerosis. Gastrointestinal …
is indicated for the treatment of patients with relapsing multiple sclerosis. Gastrointestinal …
[HTML][HTML] Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel
JT Phillips, M Hutchinson, R Fox, R Gold… - Multiple sclerosis and …, 2014 - Elsevier
Strategies for monitoring and managing the known adverse event (AE) profile of therapies
for relapsing–remitting multiple sclerosis have become key to the optimization of patient …
for relapsing–remitting multiple sclerosis have become key to the optimization of patient …
Dimethyl fumarate: a review of efficacy and practical management strategies for common adverse events in patients with multiple sclerosis
JT Phillips, S Agrella, RJ Fox - International journal of MS …, 2017 - meridian.allenpress.com
Background: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF)
is indicated for the treatment of relapsing multiple sclerosis. Flushing and gastrointestinal …
is indicated for the treatment of relapsing multiple sclerosis. Flushing and gastrointestinal …
Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE)
EJ Fox, A Vasquez, W Grainger… - … Journal of MS …, 2016 - meridian.allenpress.com
Background: In phase 3 trials, delayed-release dimethyl fumarate (DMF; also known as
gastroresistant DMF) demonstrated efficacy in relapsing-remitting multiple sclerosis (MS) …
gastroresistant DMF) demonstrated efficacy in relapsing-remitting multiple sclerosis (MS) …
相关搜索
- dimethyl fumarate gastrointestinal events
- patients with relapsing diroximel fumarate
- patients with relapsing gastrointestinal events
- incidence and mitigation gastrointestinal events
- persistence on treatment gastrointestinal events
- patients with relapsing incidence and mitigation
- interim safety diroximel fumarate
- prior therapies diroximel fumarate
- dimethyl fumarate tolerability profile
- consensus management gastrointestinal events
- patients with relapsing interim safety
- international panel gastrointestinal events
- patients with relapsing dimethyl fumarate
- patient outcomes gastrointestinal events
- monomethyl fumarate tolerability profile
- management strategies gastrointestinal events